Back in the dean's office, I crowned the pen, a deep sigh of relief leaving my lungs. It was done. The house was safe. I was safe.
As I stood up to leave, the heavy oak door opened. Dr. Fletcher entered, accompanied by a stern-looking, incredibly wealthy older man wearing a bespoke Italian suit that exuded old, silent money.
“Clara,” Dr. Fletcher said, his eyes dancing with excitement. “I’d like you to meet someone. This is Elias Thorne. He’s the head of the Global Pharmaceutical Alliance, and coincidentally, Marcus Sterling’s main corporate competitor.”
Mr. Thorne stepped forward, extending a calloused hand. “Dr. Hensley. I just saw your speech. It was the most brilliant defense of targeted molecular therapy I’ve heard in a decade.” He paused, his gaze becoming intensely sharp. “I want to personally fund the construction of your private research laboratory. Unlimited capital. But I’ll only do it under one very specific condition.”
One year later.
The air in the Hensley Oncology Laboratory was perfectly climate-controlled, carrying the faint, clean scent of ozone and sterilized glass. Located in the newly built, sunlit wing of the university's research center, it was widely considered the jewel in the institution's crown.
I stood in the center of my state-of-the-art private laboratory. The walls were lined with millions of dollars' worth of sequencing equipment, humming with quiet, obedient power. I donned a crisp, immaculate white lab coat, my name, Dr. Clara Hensley, MD/PhD, Director—embroidered in navy thread over my heart.
read more in next page
